This study will find the most effective and optimal resistance exercise training program for frail older adults, and takes into account (in)adequate protein intake and personal characteristics, in order to improve sarcopenia-related outcomes in this…
ID
Bron
Verkorte titel
Aandoening
Sarcopenia and malnutrition
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Muscle strength measured by the 1-RM
Achtergrond van het onderzoek
The world population is aging rapidly. As society ages, the incidence of physical limitations and frailty is dramatically increasing, which reduces the quality of life and increases health care expenditures. An important cause of physical limitations and frailty is the age-related loss of skeletal muscle mass, strength and performance, also referred to as sarcopenia.
Resistance-type exercise training is the most promising intervention to prevent or treat sarcopenia in older adults. Evidence of resistance exercise is based on well-controlled studies and cannot be easily translated to daily physiotherapy practice. In practice, the execution of the training protocol differs tremendously among older adults and depends on various resistance exercise training variables (e.g. load, repetitions and volume) and personal characteristics such as frailty status, gender, age, co-morbidity, nutritional status and cognitive and mental performance. As such, physiotherapists are limited in using the available training recommendations and are in need for more personalized training protocols that improve sarcopenia outcomes. In addition, dietary protein intake is suggested to be adequate to further improve sarcopenia outcomes during resistance exercise in frail older adults. More research is warranted on the impact of (in)adequate protein intake on training adaptations and sarcopenia outcomes.
Doel van het onderzoek
This study will find the most effective and optimal resistance exercise training program for frail older adults, and takes into account (in)adequate protein intake and personal characteristics, in order to improve sarcopenia-related outcomes in this heterogeneous population.
Onderzoeksopzet
- screening
- week 0: baseline measurements
- week 1: 1-RM (start of intervention)
- week 4: 1-RM
- week 8: 1-RM
- week 12 & week 13: final measurements (End of Study)
Onderzoeksproduct en/of interventie
Resistance exercise training
Blended dietary counseling
Publiek
Mohammed Benali
+31(0)642100294
m.benali@hva.nl
Wetenschappelijk
Mohammed Benali
+31(0)642100294
m.benali@hva.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Community-dwelling and-or independent living, receiving in-home care services
- Aged 65 or older
- Physical ability and willingness to execute a resistance exercise program
- Ability and willingness to comply with the protocol
- Willingness that general practitioner will be notified on study participation
- Written informed consent
- Consent of the study physician
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Inability to understand the Dutch language
- Cognitive impairment (MMSE < 15)
- Diagnosed unstable coronary heart disease (CHD), decompensated heart failure, uncontrolled hypertension or uncontrolled arrhythmias (e.g. hart failure NYHA >3)
- Diagnosed degenerative neurocognitive disorders
- COPD GOLD >3
- Use of total parenteral nutrition (TPN)
- Active medical treatment interfering with this intervention (e.g. cancer patients following systemic and immune therapy)
- Physical disabled (walking aids or mild visual impairment are not an exclusion criteria)
- Current enrollment in a fixed rehabilitation program or other intervention studies
- Palliative treatment or a life expectancy of ≤ 3 months
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Toelichting
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL8785 |
| Ander register | METC VUmc : 2020.452 |